Dosing Frequency, and Adverse Event Management With Bispecific Therapy
Panelists discuss how an early adverse event for this drug class no matter what the mechanism or target is, is cytokine release syndrome (CRS), and it tends to occur on a timescale that is predictable. When treating patients in the outpatient setting, they receive dexamethasone, given at the first fever, which is the first sign of cytokine release syndrome (CRS) and helps mitigate it.
EP: 1.Meet a 76-Year-Old Patient With Late-Line R/R MM, Unsuitable For CAR T Therapy
EP: 2.Role of Step-Up Dosing
Now Viewing
EP: 3.Dosing Frequency, and Adverse Event Management With Bispecific Therapy
EP: 4.Strategies For Management of Infections
EP: 5.Optimizing Treatment Goals and Supportive Care For Relapsed/Refractory Multiple Myeloma in Older Patients
EP: 6.Meet a 55-Year-Old Who Was Refractory to or Relapsed on BCMA CAR T Therapy
EP: 7.Patient Tolerability of Talquetamab and Use of IVIG
EP: 8.Strategizing Talquetamab Use In Relapsed/Refractory Multiple Myeloma: Balancing Efficacy, Infection Control, and Next-Line Therapy
EP: 9.Meet our 61-Year-Old Patient With Late-Line R/R on a BCMA-Targeting Bispecific
EP: 10.Dosing Strategies in Different Targets Bispecifics
EP: 11.Managing CNS and Systemic Responses In R/R MM: Monitoring and Sequencing Strategies with Elranatamab and Cilta-Cel
EP: 12.Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies
Video content above is prompted by the following:
- Can you describe the CRS and ICANS that we see with the bispecifics, both BCMA and GPRC5D, and how we are approaching treating these patients in the inpatient and outpatient setting?
Recent Videos
